Inozyme Pharma, Inc.: management transactions · United States · SEC (Form 4)

About Inozyme Pharma, Inc.

Inozyme Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company that was historically listed on the Nasdaq Global Select Market (NASDAQ) under the ticker INZY. The company focused on developing therapies that target the PPi-Adenosine Pathway, a biological pathway that plays an important role in bone health and blood vessel function. From an equity analysis perspective, Inozyme sat in a niche rare-disease biotechnology segment, where scientific barriers are high, development timelines are long, and value creation is heavily dependent on clinical execution and regulatory success. The company was built around a single lead program, INZ-701, an ENPP1 Fc fusion protein enzyme replacement therapy designed to restore pyrophosphate (PPi) and adenosine levels. In recent corporate disclosures, INZ-701 was described as being in late-stage clinical development for ENPP1 Deficiency, with potential expansion into additional indications where PPi-Adenosine pathway deficiencies contribute to disease pathology, including ABCC6 Deficiency and calciphylaxis. That makes Inozyme a classic single-asset biotech story: high upside if the asset succeeds, but meaningful concentration risk given the lack of a diversified commercial portfolio. Inozyme’s headquarters were in Boston, Massachusetts, at 321 Summer Street, Suite 400, placing it in one of the most important life-sciences clusters in the United States. The company’s business model was research- and development-driven rather than sales-driven; it had not yet commercialized products, and its market position was defined by the novelty of its science rather than by revenue scale. Its competitive advantage stemmed from its focus on a biologically validated pathway, its specialization in rare genetic diseases, and the possibility of becoming a first-in-class or best-in-class therapy in ENPP1 Deficiency if development and approval milestones were achieved. A major recent event was the acquisition by BioMarin Pharmaceutical Inc. BioMarin announced the deal on May 16, 2025 and completed the acquisition on July 1, 2025. The transaction was structured as an all-cash acquisition at $4.00 per share, and it effectively ended Inozyme’s life as an independent public company. For investors, that matters for two reasons: first, it confirms that Inozyme’s lead asset had strategic value to a larger rare-disease platform; second, it means that any SEC Form 4 insider transactions around that period should be interpreted in the context of merger-related vesting, cancellations, and cash-out events rather than ongoing public-company ownership changes. In short, Inozyme was a U.S. Nasdaq-listed rare-disease biotech, based in Boston, whose main investment thesis centered on INZ-701 until it was absorbed into BioMarin’s enzyme therapy portfolio.